Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection
- PMID: 16081925
- PMCID: PMC1234013
- DOI: 10.1128/JCM.43.8.3877-3883.2005
Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection
Abstract
To evaluate whether a new enzyme immunoassay developed for the simultaneous detection of hepatitis C virus (HCV) core antigen (Ag) and anti-HCV antibodies (anti-HCV Ab) (Monolisa HCV Ag/Ab ULTRA; Bio-Rad) could improve the early detection of HCV infection, we compared its sensitivity to that of anti-HCV, HCV core Ag, and HCV RNA assays. The populations studied included 12 blood donor samples positive for HCV RNA and HCV core Ag but negative for anti-HCV antibodies and 23 hemodialysis patients who developed anti-HCV Ab (seroconversion) during the follow-up. From these 23 individuals, 83 samples sequentially collected prior to seroconversion and 108 samples collected after seroconversion were tested. Six of 12 blood donations were positive by the HCV Ag/Ab assay. In the hemodialysis cohort, the 24 HCV RNA-negative samples were negative by the HCV Ag/Ab assay and 23 of the 59 HCV RNA-positive samples (39%) were positive. The HCV Ag/Ab assay detected HCV infection on average 21.6 days before the most sensitive antibody assay. The HCV Ag/Ab assay did not detect HCV infection as early as the HCV RNA assay (mean delay, 30.3 days) or HCV Ag assay (mean delays, 27.9, and 16.3 days by the HCV core Ag quantification assay and the HCV Ag blood screening assay, respectively). This new assay provides a notable improvement for the early detection of HCV infection during the so-called window period compared with anti-HCV Ab assays and could be a useful alternative to HCV RNA detection or HCV core Ag assays for diagnosis or blood screening when nucleic acid technologies or HCV core Ag detection are not implemented.
Similar articles
-
Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing?Transfusion. 2005 Dec;45(12):1965-72. doi: 10.1111/j.1537-2995.2005.00648.x. Transfusion. 2005. PMID: 16371051
-
Simultaneous detection of hepatitis C virus core antigen and antibodies in Saudi drug users using a novel assay.J Med Virol. 2008 Apr;80(4):603-6. doi: 10.1002/jmv.21075. J Med Virol. 2008. PMID: 18297713
-
[Use of combined detection of hepatitis C virus core antigen and antibodies to reduce the serological window-phase].Pathol Biol (Paris). 2007 Mar;55(2):121-6. doi: 10.1016/j.patbio.2006.02.005. Epub 2006 May 2. Pathol Biol (Paris). 2007. PMID: 16631320 French.
-
The role of core antigen detection in management of hepatitis C: a critical review.J Clin Virol. 2005 Feb;32(2):92-101. doi: 10.1016/j.jcv.2004.10.005. J Clin Virol. 2005. PMID: 15653411 Review.
-
The potential role of HCV core antigen testing in diagnosing HCV infection.Antivir Ther. 2012;17(7 Pt B):1431-5. doi: 10.3851/IMP2463. Epub 2012 Dec 7. Antivir Ther. 2012. PMID: 23322590 Review.
Cited by
-
PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation.Public Health Rep. 2013 Jul;128(4):247-343. doi: 10.1177/003335491312800403. Public Health Rep. 2013. PMID: 23814319 Free PMC article. No abstract available.
-
Sensitivity of hepatitis C virus core antigen and antibody combination assays in a global panel of window period samples.Transfusion. 2015 Oct;55(10):2489-98. doi: 10.1111/trf.13179. Epub 2015 May 27. Transfusion. 2015. PMID: 26013970 Free PMC article.
-
Comparison of a dual antibody and antigen HCV immunoassay to standard of care algorithmic testing.J Clin Microbiol. 2024 Oct 16;62(10):e0083224. doi: 10.1128/jcm.00832-24. Epub 2024 Sep 16. J Clin Microbiol. 2024. PMID: 39283072
-
Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging.World J Gastroenterol. 2014 Apr 7;20(13):3431-42. doi: 10.3748/wjg.v20.i13.3431. World J Gastroenterol. 2014. PMID: 24707126 Free PMC article. Review.
-
SASLT practice guidelines: management of hepatitis C virus infection.Saudi J Gastroenterol. 2012 Sep;18 Suppl(Suppl 1):S1-32. doi: 10.4103/1319-3767.101155. Saudi J Gastroenterol. 2012. PMID: 23006491 Free PMC article. No abstract available.
References
-
- Alvarez, M., D. Planelles, E. Vila, J. Montoro, and E. Franco. 2004. Prolonged hepatitis C virus seroconversion in a blood donor, detected by HCV antigen test in parallel with HCV RNA. Vox Sang. 86:266-267. - PubMed
-
- Assal, A., J. Coste, V. Barlet, S. Laperche, C. Cornillot, W. Smilovici, J. Pillonel, and G. Andreu. 2003. Application of molecular biology to blood transfusion safety: the nucleic acid testing. Transfus. Clin. Biol 10:217-226. - PubMed
-
- Barrera, J. M., B. Francis, G. Ercilla, M. Nelles, D. Achord, J. Darner, and S. R. Lee. 1995. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang. 68:15-18. - PubMed
-
- Bouvier-Alias, M., K. Patel, H. Dahari, S. Beaucourt, P. Larderie, L. Blatt, C. Hezode, G. Picchio, D. Dhumeaux, A. U. Neumann, J. G. McHutchison, and J. M. Pawlotsky. 2002. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 36:211-218. - PubMed
-
- Busch, M. 2001. Closing the windows on viral transmission by blood transfusion, p. 33-54. In S. L. Stramer (ed.), Blood safety in the new millenium. American Association of Blood Banks, Bethesda, Md.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical